SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Jens Flensted.

Slides:

Advertisements

Similar presentations

DEDICATION DES in ACS - current state Leif Thuesen, D.M.Sc., FESC, Aarhus University Hospital, Skejby, Denmark.

Advertisements

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,

SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Michael.

By D. Fisher Geometric Transformations. Reflection, Rotation, or Translation 1.

Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13

Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13

Prime and Composite Numbers. These are numbers that have only two factors – themselves and one. These are numbers that have only two factors – themselves.

DIVIDING INTEGERS 1. IF THE SIGNS ARE THE SAME THE ANSWER IS POSITIVE 2. IF THE SIGNS ARE DIFFERENT THE ANSWER IS NEGATIVE.

Who Wants To Be A Millionaire? Decimal Edition Question 1.

LEADERS LEADERS A Prospective, Randomised, Non-Inferiority Trial Comparing Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent.

Break Time Remaining 10:00.

Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.

Randomized Comparison of Provisional Side Branch Stenting versus a Two-stent Strategy for treatment of True Coronary Bifurcation Lesions Involving a Large.

Sets Sets © 2005 Richard A. Medeiros next Patterns.

1 Outcomes for Patients with ST-Elevation Myocardial Infarction in Hospitals With and Without Onsite Coronary Artery Bypass Graft Surgery: The New York.

Before Between After.

A Prospective, Randomized, "All-Comers" Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting.

Addition 1’s to 20.

25 seconds left…...

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

We will resume in: 25 Minutes.

Converting a Fraction to %

Clock will move after 1 minute

Select a time to count down from the clock above

Eight Months Angiographic Follow-up in Patients Randomized to Crush or Culotte Stenting of Coronary Artery Bifurcation Lesions The Nordic Bifurcation Stent.

Conflicts of interests for Leif Thuesen, M.D.

SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.

For the Nordic-Baltic PCI Study Group

Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.

Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,

DEDICATION Peter Clemmensen, Henning Kelbæk, Anne Kaltoft, Steffen Helqvist, Jens Flensted Lassen, Lene Kløvgaard, Christian J Terkelsen, Hans Henrik Tilsted,

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

Lisette Okkels Jensen, Per Thayssen, Henrik Steen Hansen, Evald Høj Christiansen, Hans Henrik Tilsted, Lars Romer Krusell, Anton Boel Villadsen, Anders.

Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,

The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: ischemic postconditioning during primary.

Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.

Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.

Comparison of drug-eluting stents in real-life clinical practice in Sweden: Insights from the SCAAR register. Goran K. Olivecrona 1, Elvin Kedhi 2, Elmir.

Influence of a Pressure Gradient Distal to Implanted Bare-Metal Stent on In-Stent Restenosis After Percutaneous Coronary Intervention Lisette Okkels Jensen,

The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: DEFERred stent implantation in connection.

The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: DEFERred stent implantation in connection.

Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE

The BVS-SAVE Italian registry: Bioresorbable Vascular Scaffolds

SORT-OUT VI A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Bioabsorbable-Polymer Biolimus-Eluting Stent in Patients.

Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

For the CLOSE-UP study group

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the.

Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,

Three Years Follow Up. SORT OUT II

Catheter-Based Treatment of Coronary Artery Disease

A Randomized Trial Comparing a Polymer-Free Coronary Drug-Eluting Stent With an Ultra-Thin Strut Bioresorbable Polymer-Based Drug-Eluting Stent in an All-Comers.

Two-Year Extended Follow-up in Patients Receiving a Zotarolimus-eluting Stent in the E-Five Registry Martin T. Rothman, Ian T. Meredith, Keyur Parikh,

American College of Cardiology Presented by Dr. Stephan Windecker

International Journal of Cardiology

A Randomized Trial Comparing a Polymer-Free Coronary Drug-Eluting Stent With an Ultra-Thin Strut Bioresorbable Polymer-Based Drug-Eluting Stent in an All-Comers.

Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.

For the Nordic-Baltic PCI Study Group

American Heart Association Presented by Dr. Julinda Mehilli

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Michael.

Long-term safety and efficacy of zotarolimus-eluting and sirolimus-eluting stents in routine clinical care patients 36-month follow-up in the SORT OUT.

Maintenance of Long-Term Clinical Benefit with

Ahmed A. Khattab, MD For the German Cypher Registry Investigators

Presentation transcript:

SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Jens Flensted Lassen, Klaus Rasmussen, Anders Galløe, Per Thayssen, Henning Kelbæk, Jan Ravkilde, Ulrik Abildgaard, Lisette Okkels Jensen, Evald Høj Christiansen, Knud Nørregaard Hansen, Hans Henrik Tilsted, Peter Riis Hansen, Lars Romer Krusell, Thomas Engstrøm, Jens Aarøe, Jan Skov Jensen, Hans Erik Bøtker, Steen Dalby Kristensen, Steen Z Abildstrøm, Anne Kaltoft, Michael Maeng, Morten Madsen, Søren Paaske Johnsen & Leif Thuesen

Method The study III was performed within the framework of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT). We designed the study to reflect daily clinical practice. Therefore, no control angiography or study related patient contact were scheduled. We used patient driven clinical event detection, through the Danish Civil Registration system, the National Patient Registry and the Danish Heart Registries.

PCI Organization in Denmark Population of 5,5 million inhabitants 5 high volume PCI centers Dual anti-platelet therapy in 12 mo. Danish Civil Registration System & National Patient Registry, Danish Heart Registries cause of death hospital admission diagnosis diagnosis at discharge coronary angiography PCI CABG PCI center 100 US miles

Selected Lesion Characteristics CypherEndeavorp No of treated vessels/pt1.3 +/ /- 0.8ns No of lesions/pt1.5 +/ /- 0.9ns Lesion length (mm)(16.2 +/- 10.8)(16.4 +/-10.5)ns Stents per lesion (n)1.7 +/ /- 1.1ns Stent length (mm)(19.9 +/- 12.1)(19.7 +/- 11.0)ns Stent diameter (mm)3.3 +/- 0.5 ns Lesion type A (%) ns Lesion type B (%) ns Lesion type C (%) ns Procedure time (min)31.0 +/ /- 22.8ns GPIIbIIIa treatment (%) ns

Cardiac Mortality Hazard Ratio (95% CI) 2.17 (0.75 – 6.24) p=0.14

Myocardial Infarction Hazard Ratio (95% CI) 3.47 (1.14 – 10.5) p=0.03

Definite Stent Thrombosis Hazard Ratio (95% CI) 4.62 (1.33 – 16.1) p=0.02

Clinically Significant Restenosis Hazard Ratio (95% CI) 6.59 (2.57 – 16.9) p<0.0001

Conclusion In the SORT-OUT III all-comers RCT using patient driven clinical event detection, we found increased rates of: target lesion revascularization myocardial infarction definite stent thrombosis in the Zotarolimus-Eluting Endeavor stent as compared to the Sirolimus-Eluting Cypher stent.